Princeton Capital Management LLC Sells 1,526 Shares of Zoetis Inc. (NYSE:ZTS)

Princeton Capital Management LLC lessened its position in Zoetis Inc. (NYSE:ZTS) by 13.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,962 shares of the company’s stock after selling 1,526 shares during the quarter. Princeton Capital Management LLC’s holdings in Zoetis were worth $1,623,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the period. Dunhill Financial LLC grew its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Asset Planning Inc bought a new position in Zoetis in the 4th quarter worth approximately $58,000. Finally, Quarry LP lifted its holdings in shares of Zoetis by 45.9% during the third quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after buying an additional 96 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock valued at $312,254 in the last three months. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZTS. Piper Sandler raised their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. UBS Group initiated coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley reduced their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $215.90.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $163.22 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business’s fifty day moving average price is $166.70 and its two-hundred day moving average price is $175.22. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The stock has a market capitalization of $73.09 billion, a price-to-earnings ratio of 29.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. As a group, analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.